Last edition
News about Clinical Trials
Phase 2a study findings show RESP-X demonstrated safety, favourable dosing potential and encouraging efficacy signals, supporting further clinical development for respiratory patients colonised with Pseudomonas aeruginosa.
Clinical Trials | 25/05/2026 | By News Bureau
Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer
Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.
Clinical Trials | 22/05/2026 | By News Bureau
1st ICMR Clinical Trial Meet 2026 Showcases India's Growing Role in Integrative Medicine Research
The Indian Council of Medical Research (ICMR) Annual Clinical Trial Meet 2026 highlighted India’s growing leadership in integrative medicine research, alongside new initiatives to strengthen phase 1 clinical trials and streamline ethics review for multicenter studies.
Clinical Trials | 21/05/2026 | By News Bureau
US FDA Grants Priority Review to HYRNUO for HER2-Mutated NSCLC
The US FDA has granted Priority Review (PR) to HYRNUO (sevabertinib) as a first-line treatment for HER2-mutated Non-Small Cell Lung Cancer (NSCLC), based on phase 1/2 SOHO-01 trial data.
Clinical Trials | 21/05/2026 | By News Bureau
Pfizer Reports Positive Phase 2 Results for Pediatric Pneumococcal Vaccine Program
Pfizer reports strong phase 2 results for its 25-valent pediatric pneumococcal vaccine candidate, showing enhanced serotype 3 immune response, broad protection across 25 serotypes, and a favorable safety profile ahead of Phase 3 development.
Clinical Trials | 20/05/2026 | By News Bureau
Merck's Phase 3 TroFuse-005 Trial Shows Survival Benefit of Sac-TMT in Advanced Endometrial Cancer
Merck announced that its phase 3 TroFuse-005 trial evaluating investigational antibody-drug conjugate Sacituzumab Tirumotecan (sac-TMT) met primary endpoints of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.
Clinical Trials | 19/05/2026 | By News Bureau
INmune Bio Publishes Phase 2 MINDFuL Trial Results, Advances XPro Platform in Dementia
INmune Bio published phase 2 MINDFuL trial results in NPJ Dementia, highlighting XPro’s safety, biomarker engagement, and clinical efficacy in patients with mild Alzheimer’s Disease (AD).
Clinical Trials | 18/05/2026 | By News Bureau
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of SNB-101
SN BioScience initiates first patient dosing in a global phase 1b/2 trial of SNB-101, a nanoparticle anticancer therapy for Small Cell Lung Cancer (SCLC).
Clinical Trials | 16/05/2026 | By News Bureau
AstraZeneca's Imfinzi Combination Therapy Improves Survival Outcomes in Phase 3 Bladder Cancer Trial
AstraZeneca’s phase 3 VOLGA trial demonstrated significant survival benefits with Imfinzi and enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy, marking another positive milestone in the company’s immunotherapy programme.
Clinical Trials | 15/05/2026 | By News Bureau
Regenxbio Reports Positive Pivotal Trial Results for Duchenne Gene Therapy RGX-202
Regenxbio’s investigational gene therapy RGX-202 demonstrated strong microdystrophin expression, functional gains and a favourable safety profile in Duchenne muscular dystrophy patients, supporting plans for accelerated approval and a potential commercial launch in 2027.
Clinical Trials | 15/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy